ClinicalTrials.gg
RecruitingNCT06956729GGSH-MCUpdated May 4, 2025

Multicenter Trial of Proximal Femoral Guided Growth in Children With CP and Hips at Risk of Dislocation (GGSH-MC)

An interventional study of Proximal Femoral Guided Growth. and Standard prophylactic treatment for Hips at Risk of Dislocation. in Cerebral Palsy, sponsored by Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús. Recruiting at 16 sites in Spain. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-05-04.

Sponsored by Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Oct 2024, registered Mar 2025).
  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
3 Years to 8 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.

Planned enrollment
15th of 44
42 · median 32
Started
2024
with 7 others
No phase
37 of 54
11 open now
Primary completion
2025-12
later than 12 of 16 live
Registered
47th of 54
by date

Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 15th largest by planned enrollment of the 44 interventional ones that give a count, is one of 8 that started in 2024, is one of 37 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 47th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 8 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Cerebral Palsy with a site in Spain, or all of them as a file.
02

Study summary

The Guided Growth in Spastic Hip Multicenter Study (GGSH-MC) is a prospective, multicenter, randomized controlled trial that aims to evaluate the mid-term outcomes of Proximal Femoral Guided Growth (PFGG) in children with spastic cerebral palsy (CP) and hips at risk of dislocation (HRD). Hip dislocation is a common and severe complication in children with CP, especially those who are non-ambulatory, with a reported risk of 70-90%.

The trial includes children aged 3 to 8 years with spastic CP and HRD, defined by a migration percentage (MP) between 30% and 60%. Participants will be cluster-randomized by center into two parallel groups:

  • Experimental Group: Standard prophylactic treatment for HRD + PFGG
  • Control Group: Standard prophylactic treatment for HRD only

PFGG involves insertion of a fully threaded cannulated screw across the lateral cortex and proximal femoral epiphysis under fluoroscopic guidance, with the aim of modulating growth to improve hip containment. All patients will also receive standard soft tissue surgery (adductor and/or psoas tenotomies), as clinically indicated.

Follow-up will include clinical, radiographic, and functional assessments at 3 and 6 weeks, and at 6, 12, 18, and 24 months post-intervention. The study will include a 1-year inclusion period and a 2-year follow-up, concluding in October 2027.

Primary outcome measures include radiographic indicators of hip displacement. Secondary outcomes include functional scores, complication rates, and need for further surgery. A total of 42 participants (21 per group) will provide 80% power to detect significant differences at a 0.05 significance level. Analyses will be performed using intention-to-treat principles, with subgroup and multivariate analyses to explore modifying factors.

Read the detailed description

Cerebral palsy (CP) is the leading cause of severe physical disability in childhood, with a prevalence of 1.6 per 1,000 live births in developed countries. Spastic CP, affecting 75% of patients, often leads to progressive musculoskeletal deformities due to muscle imbalance, particularly around the hip joint. Hip dysplasia is the second most common deformity, and if untreated, can progress to dislocation, especially in non-ambulatory children (GMFCS IV-V), where risk exceeds 70%.

Hip displacement in CP is attributed to spasticity of the adductors and flexors, growth-related deformities such as coxa valga and acetabular dysplasia, and limited weight-bearing. These changes can impair function, sitting tolerance, hygiene, and quality of life. Current strategies emphasize surveillance and early intervention for hips at risk of dislocation (HRD), including soft tissue surgery. However, recurrence remains high, and reconstructive surgery, while effective, is invasive and associated with significant morbidity.

Proximal Femoral Guided Growth (PFGG) is a minimally invasive technique involving medial hemiepiphysiodesis with a cannulated screw to modulate proximal femoral growth and improve containment. Though early outcomes are promising, prospective multicenter evidence is limited.

This study is a prospective, multicenter, randomized controlled trial using cluster randomization by center to compare PFGG + standard treatment versus standard treatment alone. Children aged 3-8 years with spastic CP and HRD (MP 30-60%) will be included. The primary outcome is radiographic containment. Secondary outcomes include functional scores, pain, complications, and reintervention rates. Follow-up spans 24 months.

All surgeries follow a standardized protocol. Postoperative care includes early mobilization, use of hip abduction wedge, and physical therapy. Sample size is calculated for 80% power to detect a difference in dislocation rates, requiring 42 subjects. Data will be collected using standardized CRFs and managed centrally under SEOP oversight. Adverse events will be systematically recorded.

The study has IRB approval and complies with ISO 14155, GDPR, and the Helsinki Declaration. Funding is provided by the 2023 EPOS Research Grant (€10,000). Results will be published regardless of outcome.

03

Conditions studied

  • Cerebral Palsy

Keywords

  • Proximal Femoral Guided Growth
  • Randomized Controlled Trial
  • Spastic Hip
  • Hip Dislocation
04

Who can participate

Ages eligible
3 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 3 to 8 years.
  • Diagnosis of predominantly spastic cerebral palsy (CP).
  • Any functional level according to the GMFCS.
  • Hips at risk of dislocation (HRD), unilateral or bilateral, defined by a migration percentage (MP) between 30% and 60%.

Exclusion criteria

Exclusion Criteria:

  • Children with predominantly hypotonic or dystonic types of CP.
  • Children with neuromuscular conditions other than CP.
  • Children with high surgical/anesthetic risk.
  • Documented history of reconstructive or palliative hip surgery.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    PFGG + Standard Treatment (Experimental Group A)

    Participants in this arm will receive Proximal Femoral Guided Growth (PFGG) in addition to standard prophylactic treatment for hips at risk of dislocation (HRD). The standard treatment may include adductor tenotomy (percutaneous or open) and psoas tenotomy (intrapelvic or at the lesser trochanter) as indicated. Surgery will be performed under general anesthesia, and postoperative immobilization will follow institutional protocols, including the use of a hip abduction wedge, knee immobilizers, and ankle-foot orthoses (AFO) as required. Follow-up will include standardized clinical, functional, and radiographic assessments at 3 weeks, 6 weeks, 6 months, 12 months, 18 months, and 24 months postoperatively.

    Procedure: Proximal Femoral Guided Growth. · Procedure: Standard prophylactic treatment for Hips at Risk of Dislocation.

  • Active comparator
    Standard Treatment Only (Control Group B)

    Participants in this arm will receive standard prophylactic treatment for HRD without PFGG. This may include adductor and/or psoas tenotomies based on clinical indication, performed under general anesthesia. Postoperative care will be identical to the experimental group, with standard immobilization using a hip abduction wedge, knee immobilizers, and AFOs as needed. The follow-up schedule and outcome assessments will be identical to the experimental group, ensuring consistency in data collection.

    Procedure: Standard prophylactic treatment for Hips at Risk of Dislocation.

Interventions

  • ProcedureProximal Femoral Guided Growth.

    Proximal Femoral Guided Growth (PFGG) is performed under general anesthesia with the patient in a supine position on a radiolucent table. The surgical field is prepared from the abdomen to the feet. Anatomical landmarks on the femur and femoral neck are marked to guide the procedure. A smooth guidewire (4.0-7.0 mm) is introduced parallel to the table and advanced to the lateral quarter of the femoral neck. A 1-2 cm incision is made along the lateral femur, allowing access to the vastus lateralis muscle. Fluoroscopic control is used to ensure precise guidewire placement in the proximal femoral epiphysis in both anteroposterior (AP) and lateral views. The lateral cortex is drilled, and a fully threaded cannulated screw is inserted, ensuring at least three threads reach the epiphysis for effective growth modulation. Final fluoroscopic verification is performed to confirm proper screw placement and rule out joint penetration. Continuous fluoroscopy is used if necessary. The guidewire is r

    Also known as: Guided Growth Surgery, Proximal Femoral Epiphysiodesis, Proximal Femoral Hemiepiphysiodesis

  • ProcedureStandard prophylactic treatment for Hips at Risk of Dislocation.

    Both groups will receive standard prophylactic treatment for HRD, which consists of soft tissue release procedures based on clinical indication and functional level (GMFCS classification): Adductor Tenotomy - Percutaneous or open technique, depending on contracture severity. Psoas Tenotomy - Intrapelvic approach for GMFCS levels I-III and IV (ambulatory). Lesser trochanter approach for GMFCS levels IV-V (non-ambulatory). Additional tenotomies may be performed as needed, targeting muscles contributing to hip displacement and contractures. Botulinum toxin type A may be administered to specific muscle groups if clinically indicated. Postoperative immobilization includes: Hip abduction wedge Knee immobilizers in extension Ankle-foot orthoses (AFOs), based on individual patient needs The goal of this intervention is to reduce spastic muscle imbalance, improve hip stability, and delay or prevent hip dislocation in children with spastic CP and HRD.

06

What researchers measure

Primary outcomes

  1. Migration percentage (MP). Radiological

    Percentage of the femoral head lateral to Perkins line on standardized AP pelvic radiograph. Unit of Measure: Percentage (%)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery

  2. Pelvic Obliquity (PO). Radiological

    Angle between the horizontal line and the line joining both iliac crests on AP pelvic radiograph. Unit of Measure: Degrees (°)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.

  3. Migration Percentage Adjusted for Pelvic Obliquity (PAMP). Radiological

    Modified MP accounting for pelvic tilt, measured on AP pelvic radiograph. Unit of Measure: Percentage (%)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.

  4. Acetabular Index (AI). Radiological

    Angle formed between Hilgenreiner's line and a line along the acetabular roof. Unit of Measure: Degrees (°)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.

  5. Center-Edge Angle (CEA). Radiological

    Angle between vertical line through femoral head center and a line to lateral acetabular edge. Unit of Measure: Degrees (°)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.

  6. Hilgenreiner Epiphyseal Angle (HEA). Radiological

    Angle between Hilgenreiner's line and a line along the proximal femoral physis. Unit of Measure: Degrees (°)

    Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.

Secondary outcomes

  1. Patient characteristics. Age

    Chronological age of the patient at the time of surgery. Unit of measure: years

    Time frame: At time of surgery

  2. Patient characteristics. Sex

    Biological sex of participant. Unit of Measure: Male/Female

    Time frame: Pre-surgery

  3. Patient characteristics. Gross Motor Function Classification System level (GMFCS)

    GMFCS level will be recorded to classify gross motor function. The GMFCS has five levels (I to V), with higher levels indicating more severe motor impairment. Unit of measure: scale (I to V)

    Time frame: Pre-surgery

  4. Patient characteristics. Weight

    Weight of the patient measured using a calibrated scale during the pre-surgical evaluation. Unit of measure: kilograms (kg)

    Time frame: Pre-surgery

  5. Patient characteristics. Orthopedic comorbidities

    Presence or absence of orthopedic comorbidities such as scoliosis and knee flexion contractures will be assessed.

    Time frame: Pre-surgery

  6. Patient characteristics. Respiratory disorders or gastrointestinal issues

    Presence or absence of relevant medical comorbidities, including epilepsy, respiratory disorders (e.g., obstructive sleep apnea, tracheostomy), and gastrointestinal disorders (e.g., gastrostomy), will be recorded.

    Time frame: Pre-surgery

  7. Patient characteristics. Medication use

    Current use of any medication will be recorded as a categorical variable (yes/no), along with medication type if applicable.

    Time frame: Pre-surgery

  8. Clinical variables. Pain

    Pain will be assessed using the Visual Analog Scale (VAS), a 10-cm horizontal line ranging from "no pain" to "worst imaginable pain." Higher scores indicate greater pain intensity. Unit of measure: scale (0-10)

    Time frame: Immediately after surgery; 3 and 6 weeks; 6, 12, 18, and 24 months post-surgery

  9. Clinical variables. Analgesic needs

    Analgesic requirements will be recorded based on caregiver reports. Categorical: first-line analgesics (e.g., Ibuprofen, Paracetamol \[Acetaminophen\], Metamizole), second-line analgesics (e.g., mild opioids like Tramadol), or third-line analgesics (e.g., strong opioids such as morphine and fentanyl).

    Time frame: Immediately after surgery; 3 and 6 weeks; 6, 12, 18, and 24 months post-surgery

  10. Clinical variables. Hip abduction in flexion

    Hip abduction in flexion will be measured in degrees during standardized physical examination. Unit of Measure: Degrees (º)

    Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months

  11. Clinical variables. Hip abduction in extension

    Hip abduction in extension will be measured in degrees during standardized physical examination. Unit of Measure: Degrees (º)

    Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months

  12. Clinical variables. Hip flexion contracture >20°

    Presence or absence of hip flexion contracture greater than 20 degrees will be recorded during physical examination. Yes/no

    Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months

  13. Clinical variables. Galeazzi sign

    The Galeazzi sign will be assessed to detect femoral shortening as a clinical indicator of limb length discrepancy. Presence or absence will be recorded.

    Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months

  14. Clinical variables. Pelvic obliquity

    Pelvic obliquity will be assessed clinically during physical examination and recorded as present or absent.

    Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months

  15. Functional variables

    The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) questionnaire will be completed. It is a validated measure of health-related quality of life for children with severe disabilities. Units on a scale (0-100; higher = better)

    Time frame: Pre-surgery; 12 and 24 months

  16. Concomitant treatment. Physiotherapy Frequency Per Week

    Frequency of physiotherapy: Number of Physiotherapy Sessions per Week. Sessions per week.

    Time frame: At 6 weeks; 6, 12, 18, and 24 months

  17. Concomitant treatment. Orthoses Use

    Use of orthoses: Number of hours per day the participant uses orthotic devices (e.g., hip abduction orthoses, scoliosis braces. Unit of Measure: Hours per day.

    Time frame: At 6 weeks; 6, 12, 18, and 24 months

  18. Concomitant treatment. Weight-Bearing Activity Time

    Time Spent in Weight-Bearing Activities per Day. Unit of Measure: Minutes per day.

    Time frame: At 6 weeks; 6, 12, 18, and 24 months

  19. Concomitant treatment. Participation in Complementary Therapies

    Participation in Complementary Therapies such as Hydrotherapy, hippotherapy, or other specified therapies. Unit of Measure: Yes/No.

    Time frame: At 6 weeks; 6, 12, 18, and 24 months

  20. Safety variables and parameters. Clinical complications

    Wound dehiscence, hematoma, superficial or deep infection. New symptoms not present before surgery will also be evaluated, such as pain, hip mobility limitations or stiffness, insomnia, constipation, irritability, etc. Unit of Measure of all the above: Participants

    Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery

  21. Safety variables and parameters. Radiological complications

    Loosening of epiphyseal screws, peri-implant fracture, implant breakage, progression of hip displacement, avascular necrosis of the femoral head, chondrolysis, etc. Unit of Measure: Number of participants

    Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery

  22. Safety variables and parameters. Functional complications

    Intolerance to sitting, supine or lateral positioning, difficulty in perineal care, hygiene, or dressing. Unit of Measure of all the above: Participants

    Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery

  23. Safety variables and parameters. Clavien-Dindo-Sink surgical complications classification

    Complications will be classified according to the modified Clavien-Dindo-Sink surgical complications classification. Unit of Measure: Grade (Ordinal)

    Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery

  24. Other variables. Surgical time

    Measured from skin incision to closure, quantified in minutes

    Time frame: Perioperative (intraoperative)

  25. Other variables. Postoperative hospital stay

    Measured in days, with the day of surgery as day 0.

    Time frame: From surgery to discharge

  26. Other variables. Time to comfortable wheelchair sitting

    Number of days until the patient can sit comfortably in a wheelchair after surgery (day 0), as reported by primary caregivers.

    Time frame: At 3 weeks post-surgery

  27. Other variables. Time until pain-free perineal care and hygiene

    Number of days until the patient can perform perineal care and hygiene without pain post-surgery (day 0), reported by primary caregivers during follow-up.

    Time frame: Assessed at 3 weeks post-surgery

  28. Other variables. Time to initiation of pain-free physiotherapy

    Number of days from the surgical intervention (day 0) until the patient can begin physiotherapy without pain, as reported by primary caregivers during follow-up visits.

    Time frame: Assessed at 3 weeks post-surgery

07

Study locations

16 of 16 sites recruiting
08

References and documents

Publications

  • Kiapekos N, Brostrom E, Hagglund G, Astrand P. Primary surgery to prevent hip dislocation in children with cerebral palsy in Sweden: a minimum 5-year follow-up by the national surveillance program (CPUP). Acta Orthop. 2019 Oct;90(5):495-500. doi: 10.1080/17453674.2019.1627116. Epub 2019 Jun 18. PubMed 31210072 ↗
  • Shore BJ, Yu X, Desai S, Selber P, Wolfe R, Graham HK. Adductor surgery to prevent hip displacement in children with cerebral palsy: the predictive role of the Gross Motor Function Classification System. J Bone Joint Surg Am. 2012 Feb 15;94(4):326-34. doi: 10.2106/JBJS.J.02003. PubMed 22336971 ↗
  • Hwang M, Kuroda MM, Tann B, Gaebler-Spira DJ. Measuring care and comfort in children with cerebral palsy: the care and comfort caregiver questionnaire. PM R. 2011 Oct;3(10):912-9. doi: 10.1016/j.pmrj.2011.05.017. PubMed 21852220 ↗
  • Hagglund G, Goldring M, Hermanson M, Rodby-Bousquet E. Pelvic obliquity and measurement of hip displacement in children with cerebral palsy. Acta Orthop. 2018 Dec;89(6):652-655. doi: 10.1080/17453674.2018.1519104. Epub 2018 Oct 17. PubMed 30326758 ↗
  • Narayanan UG, Fehlings D, Weir S, Knights S, Kiran S, Campbell K. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD). Dev Med Child Neurol. 2006 Oct;48(10):804-12. doi: 10.1017/S0012162206001745. PubMed 16978459 ↗
  • Birkenmaier C, Jorysz G, Jansson V, Heimkes B. Normal development of the hip: a geometrical analysis based on planimetric radiography. J Pediatr Orthop B. 2010 Jan;19(1):1-8. doi: 10.1097/BPB.0b013e32832f5aeb. PubMed 19829156 ↗
  • Foroohar A, McCarthy JJ, Yucha D, Clarke S, Brey J. Head-shaft angle measurement in children with cerebral palsy. J Pediatr Orthop. 2009 Apr-May;29(3):248-50. doi: 10.1097/BPO.0b013e31819bceee. PubMed 19305274 ↗
  • Southwick WO. Osteotomy through the lesser trochanter for slipped capital femoral epiphysis. J Bone Joint Surg Am. 1967 Jul;49(5):807-35. No abstract available. PubMed 6029256 ↗
  • Tonnis D. Normal values of the hip joint for the evaluation of X-rays in children and adults. Clin Orthop Relat Res. 1976 Sep;(119):39-47. PubMed 954321 ↗
  • Reimers J. The stability of the hip in children. A radiological study of the results of muscle surgery in cerebral palsy. Acta Orthop Scand Suppl. 1980;184:1-100. doi: 10.3109/ort.1980.51.suppl-184.01. No abstract available. PubMed 6930145 ↗
  • Onimus M, Allamel G, Manzone P, Laurain JM. Prevention of hip dislocation in cerebral palsy by early psoas and adductors tenotomies. J Pediatr Orthop. 1991 Jul-Aug;11(4):432-5. doi: 10.1097/01241398-199107000-00002. PubMed 1860938 ↗
  • Lebe M, van Stralen RA, Buddhdev P. Guided Growth of the Proximal Femur for the Management of the 'Hip at Risk' in Children with Cerebral Palsy-A Systematic Review. Children (Basel). 2022 Apr 25;9(5):609. doi: 10.3390/children9050609. PubMed 35626786 ↗
  • Hsu PJ, Wu KW, Lee CC, Lin SC, Kuo KN, Wang TM. Does screw position matter for guided growth in cerebral palsy hips? Bone Joint J. 2020 Sep;102-B(9):1242-1247. doi: 10.1302/0301-620X.102B9.BJJ-2020-0340.R1. PubMed 32862682 ↗
  • Portinaro N, Turati M, Cometto M, Bigoni M, Davids JR, Panou A. Guided Growth of the Proximal Femur for the Management of Hip Dysplasia in Children With Cerebral Palsy. J Pediatr Orthop. 2019 Sep;39(8):e622-e628. doi: 10.1097/BPO.0000000000001069. PubMed 31393306 ↗
  • Hsieh HC, Wang TM, Kuo KN, Huang SC, Wu KW. Guided Growth Improves Coxa Valga and Hip Subluxation in Children with Cerebral Palsy. Clin Orthop Relat Res. 2019 Nov;477(11):2568-2576. doi: 10.1097/CORR.0000000000000903. PubMed 31425278 ↗
  • Lee WC, Kao HK, Yang WE, Ho PC, Chang CH. Guided Growth of the Proximal Femur for Hip Displacement in Children With Cerebral Palsy. J Pediatr Orthop. 2016 Jul-Aug;36(5):511-5. doi: 10.1097/BPO.0000000000000480. PubMed 25887815 ↗
  • Chou PC, Huang YC, Hsueh CJ, Lin JG, Chu HY. Retrospective study using MRI to measure depths of acupuncture points in neck and shoulder region. BMJ Open. 2015 Jul 29;5(7):e007819. doi: 10.1136/bmjopen-2015-007819. PubMed 26224017 ↗
  • Shaw KA, Hire JM, Cearley DM. Salvage Treatment Options for Painful Hip Dislocations in Nonambulatory Cerebral Palsy Patients. J Am Acad Orthop Surg. 2020 May 1;28(9):363-375. doi: 10.5435/JAAOS-D-19-00349. PubMed 31663909 ↗
  • Shore BJ, Graham HK. Management of Moderate to Severe Hip Displacement in Nonambulatory Children with Cerebral Palsy. JBJS Rev. 2017 Dec;5(12):e4. doi: 10.2106/JBJS.RVW.17.00027. No abstract available. PubMed 29256976 ↗
  • Shrader MW, Wimberly L, Thompson R. Hip Surveillance in Children With Cerebral Palsy. J Am Acad Orthop Surg. 2019 Oct 15;27(20):760-768. doi: 10.5435/JAAOS-D-18-00184. PubMed 30998565 ↗
  • Hagglund G, Andersson S, Duppe H, Lauge-Pedersen H, Nordmark E, Westbom L. Prevention of dislocation of the hip in children with cerebral palsy. The first ten years of a population-based prevention programme. J Bone Joint Surg Br. 2005 Jan;87(1):95-101. PubMed 15686244 ↗
  • Ramstad K, Jahnsen RB, Terjesen T. Severe hip displacement reduces health-related quality of life in children with cerebral palsy. Acta Orthop. 2017 Apr;88(2):205-210. doi: 10.1080/17453674.2016.1262685. Epub 2016 Nov 28. PubMed 27892753 ↗
  • Wawrzuta J, Willoughby KL, Molesworth C, Ang SG, Shore BJ, Thomason P, Graham HK. Hip health at skeletal maturity: a population-based study of young adults with cerebral palsy. Dev Med Child Neurol. 2016 Dec;58(12):1273-1280. doi: 10.1111/dmcn.13171. Epub 2016 Jun 17. PubMed 27312016 ↗
  • Jung NH, Pereira B, Nehring I, Brix O, Bernius P, Schroeder SA, Kluger GJ, Koehler T, Beyerlein A, Weir S, von Kries R, Narayanan UG, Berweck S, Mall V. Does hip displacement influence health-related quality of life in children with cerebral palsy? Dev Neurorehabil. 2014 Dec;17(6):420-5. doi: 10.3109/17518423.2014.941116. Epub 2014 Jul 24. PubMed 25057804 ↗
  • Cornell MS. The hip in cerebral palsy. Dev Med Child Neurol. 1995 Jan;37(1):3-18. doi: 10.1111/j.1469-8749.1995.tb11928.x. No abstract available. PubMed 7828785 ↗
  • Bagg MR, Farber J, Miller F. Long-term follow-up of hip subluxation in cerebral palsy patients. J Pediatr Orthop. 1993 Jan-Feb;13(1):32-6. doi: 10.1097/01241398-199301000-00007. PubMed 8416350 ↗
  • Kerr Graham H, Selber P. Musculoskeletal aspects of cerebral palsy. J Bone Joint Surg Br. 2003 Mar;85(2):157-66. doi: 10.1302/0301-620x.85b2.14066. No abstract available. PubMed 12678344 ↗

Individual participant data

Plan to share: Yes — Participant data will be processed in accordance with current data protection legislation, including Organic Law 3/2018, of December 5, on Data Protection and Digital Rights, and the European Regulation (EU) 2016/679 (GDPR). This means that: The data controller is the Sponsor: SEOP Neuro-Orthopedics Working Group (Spanish Society of Pediatric Orthopedics). Data will be shared among study centers for statistical purposes only. Personal information is stored in medical records. Data will not leave the EU and will remain confidential. Patients may exercise their data rights and file complaints. Patients' names will not appear in any publications.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Individual participant data and supporting documentation (Study Protocol and Statistical Analysis Plan) will be available beginning 6 months after the publication of the primary results and will remain accessible for 5 years. Data access will be limited to approved researchers under controlled conditions for statistical purposes only.

Access criteria: The data controller is the Sponsor: SEOP Group (Sociedad Española de Ortopedia Pediátrica). Data will be shared among study centers for statistical purposes only. Each participant: personal information will be stored in their medical record. Only the principal investigator and collaborators will be able to identify participants, as they will manage the database linking the assigned codes to each individual. Only health authorities or the Ethics Committee will have access to this information, ensuring confidentiality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 14 months is above that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
May 4, 2025
StartActual
Oct 1, 2024
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2027
Last update
May 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06956729
Lead sponsor
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús
Collaborators
Hospital Sant Joan de Deu, Salamanca University Hospital, Complexo Hospitalario Universitario de A Coruña, Hospital General Universitario Gregorio Marañon, Hospital Universitario de Canarias, Hospital Universitario Central de Asturias, Hospital Son Espases, Hospital Universitario 12 de Octubre, Hospital Vall d'Hebron, Hospital Universitario Virgen Macarena, Hospital Miguel Servet, Hospital Donostia, Hospitales Universitarios Virgen del Rocío, Complejo Hospitalario de Navarra, Hospital Universitario Ramon y Cajal, Hospital Universitario Torrecárdenas
Responsible party
María Galán Olleros (Specialist in Orthopedic Surgery and Traumatology., Hospital Infantil Universitario Niño Jesús, Madrid, Spain) — Principal investigator
First posted
May 4, 2025
Start date
Oct 1, 2024
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
May 4, 2025

Study contacts

María Galán Olleros, M.D
Contact
mgalanolleros@gmail.com
0034660492192
María Galán Olleros, MD
principal investigator · Hospital Infantil Universitario Niño Jesús, Madrid

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion